Universal Ibogaine Corporate News



Universal Ibogaine


Universal Ibogaine Announces Engagement of Media and Investor Relations Advisors


Calgary, AB – TheNewswire – October 25, 2021 – Universal Ibogaine Inc. (TSXV:IBO) ( “UI” or the “Company” ), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has retained three additional advisors as part of the expansion of its’ market awareness and investor relations program.

Investing News Network (“ INN ”, a division of Dig Media Inc.), Belair Capital Advisors Inc. (” Belair “), and Greenshoe Media Group Inc. (“ Greenshoe ”) have been retained to support UI in enhancing the reach of its market awareness campaigns and developing productive conversations with current and future shareholders and other market participants.

Vancouver-based INN has been engaged for a six month term, during which it will assist in distribution of UI news to INN’s network of subscribers for a fee of $58,000.

Belair, based in Toronto, specializes in corporate finance advisory and messaging across various social media platforms, and will assist UI in improving market awareness and with dissemination of UI news releases. The engagement is for a term of six months, with a fee of $50,000.

Toronto based Greenshoe has been engaged to assist in media production and distribution across the BNN Bloomberg network in Canada, as well as various other financial media channels.  The contract is for a term of 6 months, with a fee of $57,000.

None of INN, Belair or Greenshoe were granted an interest in or an option to acquire any securities of the Company, and the fees payable to these advisors will be paid from the Company’s working capital on hand.  All of the contracts are subject to any necessary approval by the TSX Venture Exchange.

About Universal Ibogaine

UI is a life sciences company, with a goal to develop a platform of addiction treatment clinics, which may eventually use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants.  

UI separately plans to clinically develop ibogaine, a natural plant substance, as an authorized addiction interruption medicine for the treatment of Opioid Use Disorder.  A Clinical Trial Application to Health Canada is being developed to undertake clinical trials in Canada, aimed at proving the safety and efficacy of the use of ibogaine for this purpose.  In the longer term, UI plans to introduce ibogaine into the addiction treatment protocols to be used in its’ future facilities.

Further Information

Completion of the Offering and the QT is subject to a number of conditions, including but not limited to, TSXV acceptance. There can be no assurance that the Offering and the QT will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the filing statement which is being prepared in connection with the QT, any information released or received with respect to the transactions described herein may not be complete and should not be relied upon. An investment in the securities of the PSQ, UI or the Resulting Issuer should be considered highly speculative. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward Looking Statements


This news release contains forward-looking statements and information. More particularly, this document contains statements and information concerning the size of the Offering, the completion of the Amalgamation of the QT, PSQ’s and UI’s expectations with respect to the completion of the Offering, UI’s expectations with respect to the UI Financing, the Kelburn Acquisition and the QT. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, “potential”, or other similar words, or statements that certain events or conditions “may”, “should” or “could” occur. The forward-looking statements and information are based on certain key expectations and assumptions made by PSQ and UI, including expectations and assumptions concerning the completion of the Offering for $6 million, timing of receipt of required regulatory approval, the completion of the Kelburn Acquisition, the satisfaction of other conditions to the completion of the Offering and the QT and the completion of the QT. Although PSQ and UI believe that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PSQ and UI can give no assurance that they will prove to be correct.

Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by PSQ and UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. PSQ and UI do not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.